ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORS
11 mai 2022 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), is pleased to announce the grant of patent application no. 15/753,882...
ONCOTELIC PROVIDES 3RD QUARTER 2021 COMPARED TO 3RD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATE
23 nov. 2021 07h30 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) today announced financial results for the third quarter ended...
MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19
08 mars 2021 07h00 HE
|
Mateon Therapeutics, Inc.
PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics,...
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
01 mars 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM
22 févr. 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA
02 févr. 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON’S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT
30 déc. 2020 10h46 HE
|
Mateon Therapeutics, Inc.
-FPI FOR C001 PHASE 2 TRIAL AGAINST COVID-19 AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has...
MATEON TO HOST VIRTUAL WEBINAR ADDRESSING COVID-19 AND THERAPIES AYURVEDA AND ARTEMISIA ON DECEMBER 16, 2020
09 déc. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
Featuring Global Experts in Ayurveda and PharmacologyDecember 16, 2020 7 AM PST- 10 AM EST- 8:30 PM ISTPanel Discussion and Q & A to follow Agoura Hills, California, Dec. 09, 2020 (GLOBE...
DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST COVID-19
30 nov. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
--75% IMPROVEMENT BY DAY 2 ON ARTIVEDA™ AGOURA HILLS, California, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics...
MATEON PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS
16 nov. 2020 06h55 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today announced financial results for the third quarter ended September...